Teva Pharmaceutical Industries Ltd. has released its Q2 2026 Aide Memoire, compiled with public information previously provided by the company to assist investors ahead of its second quarter 2026 financial results. The document is available on the "Investors" page of Teva's website and is based on prior results, management's previous commentary about the business outlook, and data from select independent sources.

The company is scheduled to announce its Q2 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. A conference call and live webcast to discuss the results will follow later that day at 8:00 a.m. ET. Investors and analysts can access the webcast via Teva's investor relations website, while advance registration is required to participate in the conference call to obtain a phone number and personal PIN.

Teva Pharmaceutical Industries Ltd. is listed on the NYSE and TASE under the ticker symbol TEVA. The company operates as a biopharmaceutical firm, transforming into a leading innovative company enabled by a world-class generics business. For over 120 years, Teva has focused on neuroscience, immunology, and the provision of complex generic medicines, biosimilars, and pharmacy brands worldwide.

The announcement includes cautionary notes regarding forward-looking statements, which are based on management's current beliefs and expectations and are subject to risks and uncertainties. Factors that could cause actual results to differ include competitive pressures, execution of its Pivot to Growth strategy, significant indebtedness, and regulatory matters. These risks are detailed in Teva's Quarterly Report on Form 10-Q for the first quarter of 2026 and its Annual Report on Form 10-K for the year ended December 31, 2025.

Media inquiries can be directed to TevaCommunicationsNorthAmerica@tevapharm.com , while investor relations questions should be sent to TevaIR@Tevapharm.com .

Teva Pharmaceutical Industries Ltd. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for pediatric Tourette syndrome. The submission, supported by positive Phase 3 data recently published in JAMA Neurology, marks a significant milestone in addressing a critical unmet need for patients. If approved, ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade.

Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva, emphasized the importance of the submission. "The NDA submission for ecopipam is a significant milestone for a potential first-in-class treatment option in pediatric Tourette syndrome," Hughes stated. He added that the development reflects the momentum in Teva's innovative pipeline and advances its Pivot to Growth strategy.

The Phase 3 study demonstrated that ecopipam significantly delayed time to relapse compared with placebo in pediatric patients who had achieved a clinical response during the open-label treatment period. The study met its primary efficacy endpoint, showing a statistically significant benefit for ecopipam over placebo (p = 0.008). The therapy was generally well tolerated during the trial.

Adverse events related to ecopipam therapy were reported in the study. The most common events included somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]).

Ecopipam is a selective dopamine D1 receptor antagonist with a novel mechanism of action. It has received FDA Orphan Drug and Fast Track designations for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.

Tourette syndrome is a chronic neuro-developmental disorder characterized by involuntary motor and vocal tics, often beginning between ages 5 and 10. Despite existing treatments, many patients experience inadequate control or limiting side effects, highlighting the need for new therapeutic options.